患有不同组合模式的阿片类药物和二胺类药物的患者的风险因素和死亡率:一项回顾性研究

Fang-Yu Su^1,2, Ming-Che Tsai¹, Yee-Yung Ng³

¹Institute of Health and Welfare Policy, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Pharmacology research & perspectives

|January 16, 2026

概括

结合阿片类药物和类药物 (BZD) 显著增加死亡风险. 与仅使用阿片类药物相比,连续,新或过去的BZD与阿片类药物一起使用会增加风险,这凸显了处方谨慎.

科学领域:

药理学药理学是指药理学的学科.
公共卫生公共卫生
流行病学流行病学

背景情况:

同时使用阿片类药物和二甲 (BZD) 与呼吸系统抑郁和死亡率的风险增加有关.
了解与不同联合处方模式相关的特定死亡风险对于患者安全至关重要.

研究的目的:

评估各种二类药物 (BZD) 使用模式与阿片类药物使用者全因死亡率之间的关联.
量化与阿片类药物治疗结合的连续,新的和过去的BZD使用相关的死亡风险.

主要方法:

使用私人医院系统 (2008-2018) 数据进行的回顾性队列研究.
分析了418,549名阿片类药物使用者,根据BZD使用 (仅阿片类药物,过去使用,持续使用,新开始) 分为四组.
考克斯比例危险回归模型用于计算1年全因死亡率的调整危险比率 (aHR),控制病史和查尔森并发症指数 (CCI).

主要成果:

与仅使用阿片类药物的用户相比,在持续使用BZD的用户 (aHR=1.78),新的BZD发起者 (aHR=1.56) 和过去的BZD用户 (aHR=1.29) 中,观察到显著更高的1年死亡风险.
高龄,癌症诊断和更高的并发症负担也与死亡率的增加有关.
所有评估的二胺 (BZD) 与阿片类药物联合使用的模式都表明死亡风险增加.

结论:

同时使用阿片类药物和类药物 (BZD) 与不同使用模式的死亡率显著增加有关.
对阿片类药物和BZD的处方实践需要仔细考虑,特别是对于老年患者和具有多种并发症的患者.
这些发现强调了风险减轻策略在联合处方阿片类药物和二类药物 (BZD) 时的重要性.

关键词:

负面的结果是不利的结果.作为一种类药物,它是 benzodiazepine.共同处方的共同处方死亡率死亡率吸食阿片类药物的使用者

相关概念视频

01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.2K

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

1.2K

01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

784

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...

784

01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

865

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...

865

01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

931

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

931

01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

188

01:28

Depressants

384

Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...

384